Management of non-small-cell lung cancer: recent developments

M Reck, DF Heigener, T Mok, JC Soria, KF Rabe - The Lancet, 2013 - thelancet.com
Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide.
Therefore, improvements in diagnostics and treatments are urgently needed. In this review …

[HTML][HTML] ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

A Passaro, N Leighl, F Blackhall, S Popat, K Kerr… - Annals of …, 2022 - Elsevier
Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology

DS Ettinger, DE Wood, DL Aisner, W Akerley… - Journal of the National …, 2017 - jnccn.org
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

[HTML][HTML] Comprehensive genomic characterization of squamous cell lung cancers

Cancer Genome Atlas Research Network - Nature, 2012 - ncbi.nlm.nih.gov
Lung squamous cell carcinoma (lung SqCC) is a common type of lung cancer, causing
approximately 400,000 deaths per year worldwide. Genomic alterations in lung SqCC have …

[HTML][HTML] 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

J Vansteenkiste, L Crino, C Dooms, JY Douillard… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

[HTML][HTML] Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

KM Kerr, L Bubendorf, MJ Edelman, A Marchetti… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The Second …

Non–small cell lung cancer

DS Ettinger, W Akerley, H Borghaei, AC Chang… - Journal of the National …, 2012 - jnccn.org
Most patients with non–small cell lung cancer (NSCLC) are diagnosed with advanced
cancer. These guidelines only include information about stage IV NSCLC. Patients with …

Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)

CJ Langer, T Mok, PE Postmus - Cancer treatment reviews, 2013 - Elsevier
The prognosis for patients with relapsed/progressive non-small cell lung cancer (NSCLC)
remains poor. For first-line therapy, a number of platinum-based regimens are standard; …

[HTML][HTML] 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

B Besse, A Adjei, P Baas, P Meldgaard, M Nicolson… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non–small cell lung cancer: a multicenter …

N Navani, JM Brown, M Nankivell… - American journal of …, 2012 - atsjournals.org
Rationale: The current management of advanced non–small cell lung cancer (NSCLC)
requires differentiation between squamous and nonsquamous subtypes as well as …